Iqvia Holdings Inc (NYSE:IQV) CFO Michael R. Mcdonnell sold 9,500 shares of Iqvia stock in a transaction that occurred on Monday, December 3rd. The shares were sold at an average price of $128.35, for a total value of $1,219,325.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Shares of NYSE:IQV opened at $117.98 on Friday. Iqvia Holdings Inc has a 12 month low of $91.57 and a 12 month high of $135.48. The company has a market cap of $24.64 billion, a P/E ratio of 27.06, a PEG ratio of 1.77 and a beta of 0.81. The company has a current ratio of 1.09, a quick ratio of 1.09 and a debt-to-equity ratio of 1.41.
Iqvia (NYSE:IQV) last announced its earnings results on Monday, October 22nd. The medical research company reported $1.42 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.39 by $0.03. Iqvia had a return on equity of 13.69% and a net margin of 12.29%. The firm had revenue of $2.59 billion for the quarter, compared to analysts’ expectations of $2.58 billion. The company’s revenue was up 5.2% on a year-over-year basis. As a group, analysts anticipate that Iqvia Holdings Inc will post 5.13 earnings per share for the current fiscal year.
A number of institutional investors have recently bought and sold shares of IQV. Cutler Group LP grew its position in Iqvia by 173.3% in the second quarter. Cutler Group LP now owns 1,100 shares of the medical research company’s stock worth $109,000 after buying an additional 2,600 shares during the last quarter. Fort L.P. purchased a new position in Iqvia during the 2nd quarter worth approximately $118,000. Hamilton Lane Advisors LLC purchased a new position in Iqvia during the 3rd quarter worth approximately $121,000. Point72 Hong Kong Ltd grew its position in Iqvia by 2,115.9% during the 3rd quarter. Point72 Hong Kong Ltd now owns 975 shares of the medical research company’s stock worth $126,000 after purchasing an additional 931 shares in the last quarter. Finally, Quad Cities Investment Group LLC purchased a new position in Iqvia during the 2nd quarter worth approximately $140,000. Hedge funds and other institutional investors own 89.33% of the company’s stock.
A number of research firms have recently weighed in on IQV. Zacks Investment Research raised Iqvia from a “hold” rating to a “buy” rating and set a $142.00 price target on the stock in a report on Tuesday, October 23rd. Morgan Stanley lifted their price target on Iqvia from $130.00 to $145.00 and gave the company an “overweight” rating in a report on Monday, December 3rd. Piper Jaffray Companies lifted their price target on Iqvia to $131.00 and gave the company a “neutral” rating in a report on Tuesday, October 23rd. Wells Fargo & Co lifted their price target on Iqvia from $120.00 to $140.00 and gave the company an “outperform” rating in a report on Monday, August 13th. Finally, Barclays lifted their price target on Iqvia from $130.00 to $140.00 and gave the company an “overweight” rating in a report on Tuesday, October 23rd. Five analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $134.41.
Iqvia Company Profile
IQVIA Holdings Inc provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services.
Recommended Story: Discount Rate
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.